{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:24:23Z","timestamp":1769203463867,"version":"3.49.0"},"reference-count":42,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2014,4,1]]},"DOI":"10.1188\/14.cjon.e12-e18","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T22:05:10Z","timestamp":1395957910000},"page":"E12-E18","source":"Crossref","is-referenced-by-count":6,"title":["Patient Empowerment in the Management of Chronic Myeloid Leukemia"],"prefix":"10.1188","volume":"18","author":[{"given":"Melanie","family":"Coleman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/bjc.1998.396","article-title":"Predictors of patients' mental adjustment to cancer: Patient characteristics and social support","volume":"77","author":"T. Akechi","year":"1998","journal-title":"British Journal of Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pon.3026","article-title":"Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature","volume":"22","author":"P. Allart","year":"2013","journal-title":"Psycho-Oncology"},{"key":"3","unstructured":"American Cancer Society. (2013). <i>Cancer treatment and survivorship facts and figures 2012-2013.<\/i> Retrieved from <a target=\"_blank\" href='http:\/\/bit.ly\/1gMUoRM'>http:\/\/bit.ly\/1gMUoRM<\/a>"},{"key":"4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2337\/diacare.18.7.943","article-title":"Patient empowerment. Results of a randomized controlled trial","volume":"18","author":"R. Anderson","year":"1995","journal-title":"Diabetes Care"},{"key":"5","unstructured":"ARIAD Pharmaceuticals Inc. (2012). <i>Iclusig\u00ae (ponatinib)<\/i> [Package insert]. Cambridge, MA: Author."},{"key":"6","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/jco.2011.34.7146","article-title":"Success story of targeted therapy in chronic myeloid leukemia: A population-based study of patients diagnosed in Sweden from 1973 to 2008","volume":"29","author":"M. Bj\u00f6rkholm","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"7","unstructured":"Bristol-Myers Squibb. (2013). <i>Sprycel\u00ae (dasatinib)<\/i> [Package insert]. Princeton, NJ: Author."},{"key":"8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.jval.2012.08.2210","article-title":"Measuring health-related quality of life in leukemia: The Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire","volume":"15","author":"D. Cella","year":"2012","journal-title":"Value in Health"},{"key":"9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.JNR.0000387487.86309.07","article-title":"A study of the empowerment process for cancer patients using Freire's dialogical interviewing","volume":"12","author":"L. Chang","year":"2004","journal-title":"Journal of Nursing Research"},{"key":"10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: An evaluation of the World Health Organization proposal","volume":"106","author":"J. Cortes","year":"2006","journal-title":"Cancer"},{"key":"11","first-page":"1126","article-title":"International randomized study of interferon versus STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"M. Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"12","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"B. Druker","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"13","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group","volume":"91","author":"F. Efficace","year":"2012","journal-title":"Annals of Hematology"},{"key":"14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"L. Eliasson","year":"2011","journal-title":"Leukemia Research"},{"key":"15","unstructured":"European Organisation for Research and Treatment of Cancer. (2013). EORTC QOL Module for Chronic Myeloid Leukaemic (CML). Retrieved from <a target=\"_blank\" href='http:\/\/bit.ly\/1hvNUdu'>http:\/\/bit.ly\/1hvNUdu<\/a>"},{"key":"16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"F. Giles","year":"2013","journal-title":"Leukemia"},{"key":"17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.soncn.2011.02.003","article-title":"The challenges of oral agents as antineoplastic treatments","volume":"27","author":"B. Given","year":"2011","journal-title":"Seminars in Oncology Nursing"},{"key":"18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1369-7625.2007.00454.x","article-title":"The role and value of written information for patients about individual medicines: A systematic review","volume":"10","author":"J. Grime","year":"2007","journal-title":"Health Expectations"},{"key":"19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40271-013-0006-3","article-title":"The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: Qualitative insights using a global ethnographic approach","volume":"6","author":"F. Guilhot","year":"2013","journal-title":"Patient"},{"key":"20","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A. Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"X. Huang","year":"2012","journal-title":"Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"T. Hughes","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.pec.2004.08.006","article-title":"Preferences for medical collaboration: Patient-physician congruence and patient outcomes","volume":"57","author":"K. Jahng","year":"2005","journal-title":"Patient Education and Counseling"},{"key":"24","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience","volume":"119","author":"H. Kantarjian","year":"2012","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H. Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"H. Kantarjian","year":"2011","journal-title":"Blood"},{"key":"27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"H. Kantarjian","year":"2011","journal-title":"Lancet Oncology"},{"key":"28","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"H. Kantarjian","year":"2012","journal-title":"Blood"},{"key":"29","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"R. Larson","year":"2012","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/jco.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D. Marin","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3322\/caac.20093","article-title":"Self-management: Enabling and empowering patients living with cancer as a chronic illness","volume":"61","author":"R. McCorkle","year":"2011","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"32","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study","volume":"113","author":"L. Noens","year":"2009","journal-title":"Blood"},{"key":"33","unstructured":"Novartis Pharmaceuticals. (2012a). <i>Gleevec\u00ae (imatinib mesylate)<\/i> [Package insert]. East Hanover, NJ: Author."},{"key":"34","unstructured":"Novartis Pharmaceuticals. (2012b). <i>Tasigna\u00ae (nilotinib)<\/i> [Package insert]. East Hanover, NJ: Author."},{"key":"35","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"P. Nowell","year":"1960","journal-title":"Journal of the National Cancer Institute"},{"key":"36","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"S. O'Brien","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"37","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2007.10.004","article-title":"Challenges of oral medications in patients with advanced breast cancer","volume":"23","author":"F. Palmieri","year":"2007","journal-title":"Seminars in Oncology Nursing"},{"key":"38","unstructured":"Pfizer Inc. (2012). <i>Bosulif\u00ae (bosutinib)<\/i> [Package insert]. New York, NY: Author."},{"key":"39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00002820-200607000-00009","article-title":"Caregivers' role in breaking bad news: Patients, doctors, and nurses' points of view","volume":"29","author":"M. Rassin","year":"2006","journal-title":"Cancer Nursing"},{"key":"40","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G. Saglio","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1188\/12.ONF.E70-E83","article-title":"Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: A literature review [Online exclusive]","volume":"39","author":"J. Tariman","year":"2012","journal-title":"Oncology Nursing Forum"},{"key":"42","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.1200\/jco.2010.28.15_suppl.6133","article-title":"Symptom burden in chronic myeloid leukemia (CML) [Abstract]","volume":"28","author":"L. Williams","year":"2010","journal-title":"Journal of Clinical Oncology"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/M58P5M25V5414231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:06Z","timestamp":1763754846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/18\/2\/patient-empowerment-management-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,27]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4,1]]}},"alternative-id":["M58P5M25V5414231"],"URL":"https:\/\/doi.org\/10.1188\/14.cjon.e12-e18","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,27]]}}}